On January 29, 2018, PDCI released a report critically evaluating Health Canada’s plan to change how patented medicine prices are regulated in Canada.

PDCI’s report – entitled Proposed Amendments to the Patented Medicines Regulations: A Critical Appraisal of the Cost-Benefit Analysis – includes perspectives on the Regulatory Impact Assessment Statement published in Canada Gazette Part 1, and a quantitative reanalysis of the Health Canada cost-benefit analysis which supports the proposed changes.

PDCI’s report investigates the extent to which the proposed changes will impact the balance among three key factors: the affordability of medicines, their availability in Canada, and the need to support a vibrant life-sciences sector. Its aim is to help policy-makers and all Canadians to critically assess how these proposed changes could impact Canadians and whether they truly represent the right course of action for Canada.

For more information, please find the full report available on the PDCI website.

Newsletter Sign Up

TargetPharma

TargetPharma is a free e-mail newsletter featuring the latest developments on pricing and reimbursement in the pharmaceutical industry at the provincial and federal levels. Subscribers stay informed on the current activities at the PMPRB, the Common Drug Review Directorate, Health Canada and emerging issues in Canada.